22 citations
,
November 1979 in “Archives of dermatology” A woman with Fox-Fordyce disease had symptom relief using tretinoin cream.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
52 citations
,
July 2011 in “PubMed” TRPS1 is crucial for bone, kidney, and hair follicle development.
13 citations
,
March 2014 in “Journal of the American Medical Directors Association” Trichotillomania was successfully treated with risperidone and naltrexone.
Retinoids can help treat skin pigmentation disorders by affecting melanin production.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
January 2025 in “Scholarly Commons (University of Pennsylvania)” UTX is important for skin health and its loss can lead to skin issues, especially in females.
7 citations
,
June 2010 in “Journal of The American Academy of Dermatology” Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
11 citations
,
February 2023 in “British Journal of Pharmacology” Isoxazole 9 (ISX9) may help regrow hair by activating certain cell signals.
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Krox20 is important for maintaining stem cells in the skin and affects hair growth and color.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
November 2023 in “PubMed” Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
3 citations
,
August 2022 in “International Journal of Molecular Sciences” TSC2-/meth cells can cause skin lesions, hair growth, and lung issues, and may be treated with chromatin remodeling agents.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
124 citations
,
April 2000 in “Nature biotechnology” 59 citations
,
November 2011 in “Development” Trps1 is essential for proper hair follicle development.
March 2026 in “Journal of Enzyme Inhibition and Medicinal Chemistry” PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.
December 2025 in “Pediatric Dermatology” Trametinib can cause skin issues, but they can often be managed without stopping the drug.
October 2025 in “Quantum Journal of Medical and Health Sciences” Tridax procumbens is a plant with many health benefits, including healing, protecting the liver, fighting infections, and promoting hair growth.
15 citations
,
July 2000 in “The journal of investigative dermatology/Journal of investigative dermatology” Fluorescence can effectively measure acne treatment progress.
31 citations
,
November 2015 in “PloS one” Reducing Tyrosinase prevents mature color pigment cells from forming in mouse hair.
1 citations
,
December 2018 in “Journal of genetic medicine” A small change in the TRPS1 gene leads to a less severe form of a syndrome affecting hair, nose, and finger development.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
33 citations
,
August 1993 in “FEBS Letters” A new enzyme in rats may help regulate hair growth.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
1 citations
,
April 2022 in “Journal of cosmetic dermatology” Krox20 overexpression in fibroblasts may play a role in abnormal scar formation and could be a target for new treatments.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.